BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29220019)

  • 1. Amgen cholesterol antibody feud could kill key IP rule.
    Ratner M
    Nat Biotechnol; 2017 Dec; 35(12):1118-1119. PubMed ID: 29220019
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotechnology products and university-based science.
    Sobolski GK
    JAMA; 2005 Jun; 293(23):2862; author reply 2863. PubMed ID: 15956629
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotechnology products and university-based science.
    Korn D; Heinig SJ
    JAMA; 2005 Jun; 293(23):2862-3; author reply 2863. PubMed ID: 15956628
    [No Abstract]   [Full Text] [Related]  

  • 4. Enforcing pharmaceutical and biotech patent rights in China.
    Zhang YP; Deng MM
    Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760
    [No Abstract]   [Full Text] [Related]  

  • 5. "Obvious to try": a proper patentability standard in the pharmaceutical arts?
    Trask AV
    Fordham Law Rev; 2008 Apr; 76(5):2625-68. PubMed ID: 18546581
    [No Abstract]   [Full Text] [Related]  

  • 6. [Patent rights and the free research. The boundary between basic research and private sector is not longer razor-sharp].
    Westerlund L
    Lakartidningen; 2005 Sep 26-Oct 2; 102(39):2737. PubMed ID: 16245544
    [No Abstract]   [Full Text] [Related]  

  • 7. Biotechnology patent disputes. Market machinations.
    Gershon D
    Nature; 1990 Apr; 344(6269):800. PubMed ID: 2330035
    [No Abstract]   [Full Text] [Related]  

  • 8. Cabilly patent finale.
    Waltz E
    Nat Biotechnol; 2008 Aug; 26(8):846. PubMed ID: 18688222
    [No Abstract]   [Full Text] [Related]  

  • 9. Biotechnology products and university-based science.
    Lempert P
    JAMA; 2005 Jun; 293(23):2861-2; author reply 2863. PubMed ID: 15956627
    [No Abstract]   [Full Text] [Related]  

  • 10. India's IP snub.
    Jayaraman KS
    Nat Biotechnol; 2008 Apr; 26(4):362. PubMed ID: 18392000
    [No Abstract]   [Full Text] [Related]  

  • 11. "Ganske" threatens biotechnology patents worldwide.
    Glaser V
    Nat Biotechnol; 1997 Feb; 15(2):121. PubMed ID: 9035128
    [No Abstract]   [Full Text] [Related]  

  • 12. Patent fight sparks biological warfare in the drug industry.
    Fortune; 2000 Jul; 142(3):40, 42. PubMed ID: 11066662
    [No Abstract]   [Full Text] [Related]  

  • 13. Patent prosecution of biotechnology and pharmaceutical patents in a changing legal landscape.
    Lu DL; Kowalski TJ; Jarecki-Black J
    Future Med Chem; 2010 Jan; 2(1):7-9. PubMed ID: 21426040
    [No Abstract]   [Full Text] [Related]  

  • 14. Robert Stoll. Interview by Charlotte Harrison.
    Stoll R
    Nat Rev Drug Discov; 2009 Dec; 8(12):926. PubMed ID: 19949397
    [No Abstract]   [Full Text] [Related]  

  • 15. China tightens IP protection, but concerns linger.
    Jia H
    Nat Biotechnol; 2009 Sep; 27(9):787-8. PubMed ID: 19741619
    [No Abstract]   [Full Text] [Related]  

  • 16. Court upholds infringement of research tool patents, but discounts damages.
    Maebius SB; Warburg RJ
    Pharmacogenomics; 2003 Jul; 4(4):369-70. PubMed ID: 12831314
    [No Abstract]   [Full Text] [Related]  

  • 17. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.
    Teitelbaum R; Cohen M
    Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990
    [No Abstract]   [Full Text] [Related]  

  • 18. Science and the law. Working through the patent problem.
    Walsh JP; Cohen WM; Arora A
    Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928
    [No Abstract]   [Full Text] [Related]  

  • 19. US courts narrow patent exemptions.
    Fox JL
    Nat Biotechnol; 2003 Aug; 21(8):834. PubMed ID: 12894182
    [No Abstract]   [Full Text] [Related]  

  • 20. Proposed changes to patent code loom over biotech industry.
    Coombs A
    Nat Biotechnol; 2007 Dec; 25(12):1333-4. PubMed ID: 18066010
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.